Cargando…

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials

INTRODUCTION: Adjunctive mealtime use of the amylin analog pramlintide improves postprandial hyperglycemia in patients with type 1 diabetes. This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide. METHODS: Patients received mealtime pra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrmann, Kathrin, Brunell, Steven C., Li, Yan, Zhou, Ming, Maggs, David G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882374/ https://www.ncbi.nlm.nih.gov/pubmed/27071768 http://dx.doi.org/10.1007/s12325-016-0326-5

Ejemplares similares

Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials
por: Herrmann, Kathrin, et al.
Publicado: (2016)

Pramlintide in the Management of Insulin-Using Patients with Type 2 and Type 1 Diabetes
por: Pullman, John, et al.
Publicado: (2006)

Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
por: Ryan, Gina, et al.
Publicado: (2009)

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes
por: Riddle, M. C., et al.
Publicado: (2015)

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
por: Riddle, Matthew, et al.
Publicado: (2009)

Ultra‐Fast Insulin–Pramlintide Co‐Formulation for Improved Glucose Management in Diabetic Rats
por: Maikawa, Caitlin L., et al.
Publicado: (2021)

Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes
por: Weinzimer, Stuart A., et al.
Publicado: (2012)

Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
por: Qiao, Yong-Chao, et al.
Publicado: (2017)

The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro
por: Safaeian, Leila, et al.
Publicado: (2020)

Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
por: Yang, Yuanzheng, et al.
Publicado: (2022)

Study of forced degradation behavior of pramlintide acetate by HPLC and LC–MS
por: Yuan, Yu, et al.
Publicado: (2017)

Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
por: Mousa, Youssef M., et al.
Publicado: (2020)

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

A co-formulation of supramolecularly stabilized insulin and pramlintide enhances meal-time glucagon suppression in diabetic pigs
por: Maikawa, Caitlin L., et al.
Publicado: (2020)

A Phase 2 Evaluation of a Novel Co-Formulation of Pramlintide and Regular Insulin to Improve Postprandial Glycemic Control in Adults with Type 1 Diabetes (T1D)
por: Edelman, Steven Victor, et al.
Publicado: (2021)

Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide
por: Nuñez-Diaz, Cristina, et al.
Publicado: (2023)

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
por: Smith, Steve R., et al.
Publicado: (2008)

Author Correction: Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
por: Mousa, Youssef M., et al.
Publicado: (2020)

Zn(II) binding to pramlintide results in a structural kink, fibril formation and antifungal activity
por: Dudek, Dorota, et al.
Publicado: (2022)

Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis
por: Brath, Helmut, et al.
Publicado: (2017)

Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide
por: Tyagi, Puneet, et al.
Publicado: (2022)

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
por: Gallo, Silvina, et al.
Publicado: (2020)

Post hoc depression analysis from a pharmacist-led diabetes trial
por: Bateman, M. Thomas, et al.
Publicado: (2023)

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
por: Liu, Jie, et al.
Publicado: (2019)

Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells
por: Wu, Xinghuo, et al.
Publicado: (2017)

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
por: Goadsby, Peter J, et al.
Publicado: (2019)

Impact of intensive lifestyle intervention on gut microbiota composition in type 2 diabetes: a post-hoc analysis of a randomized clinical trial
por: Wei, Shaodong, et al.
Publicado: (2021)

Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes: Post hoc epidemiologic analysis of the ACCORD trial
por: Punthakee, Zubin, et al.
Publicado: (2012)

Self-weighing frequency and the incidence of type 2 diabetes: post hoc analysis of a cluster-randomized controlled trial
por: Sakane, Naoki, et al.
Publicado: (2020)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
por: Hoogwerf, Byron J, et al.
Publicado: (2008)

SAT-LB028 Efficacy and Safety of Pramlintide as an Adjunct to Insulin U500 Therapy in Veterans with Severe Insulin Resistance
por: Oprea, Mihaela, et al.
Publicado: (2019)

HbA(1c) Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
por: Kwan, Anita Y.M., et al.
Publicado: (2022)

Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis
por: Kaňovský, Petr, et al.
Publicado: (2021)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2023)

Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
por: Gilbert, Richard E., et al.
Publicado: (2017)

Changes in the lipidome in type 1 diabetes following low carbohydrate diet: Post‐hoc analysis of a randomized crossover trial
por: Al‐Sari, Naba, et al.
Publicado: (2021)

Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
por: Wretlind, Asger, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rg7uq1se3e62srkds8vasamero